Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
/in Breast Cancer, Dendritic Cells, Hypernephroma, International Publications /von 2011-10-20 / J Transl Med 2011 Oct;9:178Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2011-10-18 / Int. Immunopharmacol. 2011 Dec;11(12):2200-7Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2011-10-15 / Immunopharmacol Immunotoxicol 2012 Jun;34(3):465-9Current vaccination strategies for prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-10-03 / Eur. Urol. 2012 Feb;61(2):290-306Proving the principle: dendritic cell-based vaccines in urogenital cancers
/in Dendritic Cells, Hypernephroma, International Publications, Prostate Cancer /von 2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-7Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2011-09-28 / Clin. Dev. Immunol. 2011;2011:249281A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-84Current immunotherapeutic approaches in pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2011-09-14 / Clin. Dev. Immunol. 2011;2011:267539Immunotherapy in human glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-08-31 / Rev. Neurol. (Paris) 2011 Oct;167(10):668-72IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de